High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.

Yasuo MiyoshiYuta YoshimuraKenichi SaitoKenzo MuramotoMichiko SugawaraKarenza AlexisKenichi NomotoSeigo NakamuraToshiaki SaekiJunichiro WatanabeJose Manuel Perez-GarciaJavier Cortes

Published in: Breast cancer (Tokyo, Japan) (2020)

www.ClinicalTrials.gov code: NCT00388726.

Keyphrases

metastatic breast cancer
peripheral blood
emergency department
primary care
randomized controlled trial
clinical trial
combination therapy